Navigation Links
Access Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference
Date:11/6/2008

c agent that combines multiple modes of action to overcome drug resistance. Access is also developing Phenylbutyrate ("PB"), an HDAC inhibitor and differentiating agent currently a Phase 2 clinical candidate. For additional information on Access Pharmaceuticals, please visit our website at http://www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: early results from our clinical trial, Access' plans to continue and initiate clinical trials, the value of its products in the market, its ability to achieve clinical and commercial success and its ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited Access' need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access' Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.


'/>"/>
SOURCE Access Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Radiation Therapy Oncology Group and US Oncology Enter Collaboration to Increase Patient Access to National Clinical Trials
2. GeoVax Labs, Inc. Information To Be Available Through Standard & Poors Market Access Program
3. Mymetics Corporation Information to be Available Through Standard & Poors Market Access Program
4. Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America
5. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
6. NxStage Announces Access to Demographic and Outcomes Information for the Growing U.S. Daily Home Hemodialysis Patient Population
7. Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeutics
8. AMT Starts Collaboration With St. Jude Childrens Research Hospital on Gene Therapy for Hemophilia B. Company Accesses Exclusive Commercial Rights to Final Therapy
9. Access Pharmaceuticals Signs Merger Agreement to Acquire MacroChem Corp.
10. Huifeng Bio-Pharmaceutical (HFGB) Information to Be Available Through Standard & Poors Market Access Program
11. Access Pharmaceuticals Presents New Data at International Symposium Showing Companys Angiolix(R) Monoclonal Antibody has Potential to Treat Cancer by Attacking Cancer Stem Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... , March 2, 2015 ... to bottom.   Moments ago, Analysts Review ... Sunshine Heart (NASDAQ: SSH ), Synergetics ... Syneron Medical (NASDAQ: ELOS ), Spectranetics (NASDAQ: ... Analysts Review provides a single unified platform for investors, to ...
(Date:3/2/2015)... , March 2, 2015 VG ... developing therapies for autoimmune and infectious diseases, announced ... has issued an important new composition of matter ... through the targeting of CLIP. ... technology underlying VG Life Sciences, VG1177, a synthetic ...
(Date:3/2/2015)... MIAMI (PRWEB) March 02, 2015 ... a newly formed alliance with Shenzhen HANK Bioengineering ... M.D., Ph.D. The alliance will establish a stem ... Guangdong Province, China in September 2015. , Shenzhen ... by Zhang, an award-winning scientist, microbiologist and virologist, ...
(Date:3/1/2015)... London, UK (PRWEB) March 01, 2015 ... a partnership agreement for quality market research promotion ... and sell research reports worked out by DataGroup ... Department at Market Publishers Ltd, commented on the ... to have DataGroup Booksellers in our team of ...
Breaking Biology Technology:Quarterly Report Card of Biotechnology Companies: New Research on Sunshine Heart, Synergetics USA, Syneron Medical, Spectranetics and Thoratec 2Quarterly Report Card of Biotechnology Companies: New Research on Sunshine Heart, Synergetics USA, Syneron Medical, Spectranetics and Thoratec 3Quarterly Report Card of Biotechnology Companies: New Research on Sunshine Heart, Synergetics USA, Syneron Medical, Spectranetics and Thoratec 4VG Life Sciences Granted Key Composition Of Matter Patent 2VG Life Sciences Granted Key Composition Of Matter Patent 3Global Stem Cells Group Announces Alliance with HANK Bioengineering Co., Ltd. in Shenzhen, China 2Global Stem Cells Group Announces Alliance with HANK Bioengineering Co., Ltd. in Shenzhen, China 3Market Publishers Ltd and DataGroup Booksellers Sign Partnership Agreement 2Market Publishers Ltd and DataGroup Booksellers Sign Partnership Agreement 3
... 24 GeneGo, Inc., the leading,systems biology ... licensed,MetaCore(TM). VTT develops novel high-throughput methods for ... is in investigating,mechanisms of cancer development and ... the mechanism of action of,anti-cancer compounds. VTT ...
... of nanotechnology to electronics, photonics and renewable energy will ... held from August 10 to 14, 2009 at McMaster ... will also be presented in conjunction with the event. ... Summer School (NGC2009) and the 14th Canadian Semiconductor Technology ...
... Physicists at UC Riverside have made an ... to change how information in computers can be ... electrons, a property electrons possess that makes them ... in the development of spin-based semiconductor technology such ...
Cached Biology Technology:VTT Technical Research Centre of Finland Licenses MetaCore from GeneGo for Cancer Research and Diagnostics 2Joint nanotechnology forum to focus on electronics, photonics, renewable energy 2Discovery by UC Riverside physicists could enable development of faster computers 2Discovery by UC Riverside physicists could enable development of faster computers 3
(Date:2/19/2015)... Research and Markets ( http://www.researchandmarkets.com/research/kx9zp8/military ... "Military Electro-Optical / Infrared Systems Market by Type, ... Forecast to 2020" report to their offering. ... is expected to reach $16.35 billion by 2020, ... This report segments the military electro-optical/infrared systems market ...
(Date:2/11/2015)... , February 11, 2015 ... research report "Access Control Market by Product (Cards and ... Residential, Military and Defense, Government, Industrial, Healthcare, Education) and ... published by MarketsandMarkets, the Access Control Market ... 2020, growing at a CAGR of 10.6% ...
(Date:2/5/2015)... 2015   Epic Sciences , a precision diagnostics company ... Murali Prahalad , Ph.D., president and CEO, is scheduled ... (PMWC) 2015: Silicon Valley, which is taking place at the ... on January 26-28, 2015. Dr. Prahalad ... Biomarkers." Last year, Epic Sciences was a finalist in the ...
Breaking Biology News(10 mins):Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 3Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2
... 6, 2011 -- One of the holy grails in diabetes ... and to find drugs that target these molecules. Now, JDRF-funded ... done both, discovering not only a protein that regulates beta ... The work appears in the September 7 issue of ...
... new discovery by the University of Colorado Boulder and ... tiny "power plants" within cells known as mitochondria has ... diseases and conditions due to mitochondrial defects. Led ... in collaboration with the UC-Davis team led by Professor ...
... Peripheral arterial disease, or PAD, is a common ... older that may be a signal of future heart ... unaware they have it, says the Society of Interventional ... of Interventional Radiology,s national screening program, Legs For Life, ...
Cached Biology News:Researchers identify new drug target that stimulates 2New cellular surprise may help scientists better understand human mitochondrial diseases 2Interventional radiologists: Learn about peripheral arterial disease and get moving 2Interventional radiologists: Learn about peripheral arterial disease and get moving 3
... EPS 1001 Power Supply, 1. ... maximum.Constant voltage, constant current, and constant ... read-outs for precision and reproducibility.Stores and ... ultrathin flatbed gels on Multiphor ...
Human CCL26/Eotaxin-3 MAb (Clone 115002)...
Prostaglandin E2 Luminex Standard Product Lines: Unspecified...
Request Info...
Biology Products: